scholarly journals Targeted Intraoperative Radiation Therapy Tumor Bed Boost During Breast-Conserving Surgery After Neoadjuvant Chemotherapy in TNBC and HER2 Positive Breast Cancer

2016 ◽  
Vol 96 (2) ◽  
pp. E6-E7
Author(s):  
H.C. Kolberg ◽  
G. Loevey ◽  
L. Akpolat-Basci ◽  
M. Stephanou ◽  
P.A. Fasching ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Radiation Therapy ◽  
Neoadjuvant Chemotherapy ◽  
Breast Conserving Surgery ◽  
Intraoperative Radiation Therapy ◽  
Her2 Positive ◽  
Intraoperative Radiation ◽  
Tumor Bed ◽  
Tumor Bed Boost ◽  
Positive Breast Cancer

Targeted intraoperative radiotherapy tumor bed boost during breast conserving surgery after neoadjuvant chemotherapy in hormone receptor positive HER2 negative breast cancer.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e12090-e12090 ◽  
Author(s):  
Hans-Christian Kolberg ◽  
Gyoergy Loevey ◽  
Leyla Akpolat-Basci ◽  
Miltiades Stephanou ◽  
Peter A. Fasching ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Overall Survival ◽  
Neoadjuvant Chemotherapy ◽  
Hormone Receptor ◽  
Intraoperative Radiotherapy ◽  
Breast Conserving Surgery ◽  
Tumor Bed ◽  
Hormone Receptor Positive ◽  
Whole Breast Radiotherapy ◽  
Tumor Bed Boost

e12090 Background: Targeted intraoperative radiotherapy (TARGIT – IORT) as a tumor bed boost during breast conserving surgery is an established option for women with early breast cancer. In a previous study our group could show a beneficial effect of TARGIT-IORT on overall survival after neoadjuvant chemotherapy compared to an external boost in an unselected cohort. In this study we present an analysis of the hormone receptor positive HER2 negative subgroup. Methods: In this non-randomized cohort study involving 46 hormone receptor positive HER2 negative patients after NACT we compared outcomes of 21 patients who received a tumour bed boost with IORT (TARGIT-IORT) during lumpectomy versus 25 patients treated in the previous 13 months with external (EBRT) boost. All patients received whole breast radiotherapy. Disease free survival (DFS) and overall survival (OS) were compared. Results: There were no statistical differences between the two groups regarding tumor size, grading, nodal status and pCR rates. Median follow up was 49 months. Whereas DFS was not significantly different between the groups the 5-year Kaplan-Meier estimate of OS was significantly better by 21% with IORT: TARGIT-IORT 0 events 100%, EBRT 5 events 79%, log rank p = 0.028. Conclusions: Although our results have to be interpreted with caution due to a possible selection bias and the small numbers, we could show that the improved OS as previously demonstrated in our dataset for TARGIT-IORT during lumpectomy after neoadjuvant chemotherapy as a tumor bed boost compared to an external beam radiotherapy boost is driven by the hormone receptor positive HER2 negative subgroup. These data give further support to the inclusion of such patients in the TARGIT-B (Boost) randomised trial that is testing whether IORT boost is superior to EBRT boost and to the analysis of subgroups based on tumor biology in this trial.

Intraoperative radiotherapy in patients with breast cancer treated by breast-conserving therapy

2012 ◽  
Vol 98 (6) ◽  
pp. 736-742 ◽  
Author(s):  
Yan-jun Zhang ◽  
Lei Liu ◽  
Lin Ma ◽  
Wei Yu ◽  
Mei Liu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Radiation Therapy ◽  
Skin Color ◽  
Intraoperative Radiotherapy ◽  
Breast Conserving Surgery ◽  
Chinese Patients ◽  
Intraoperative Radiation Therapy ◽  
Breast Cancer Patients ◽  
Short Term ◽  
Intraoperative Radiation

Objective To assess the safety, cosmetic effects, and clinical efficacy of breast-conserving surgery combined with intraoperative radiation therapy for the treatment of Chinese patients with breast cancer. Methods Breast-conserving surgery combined with intraoperative radiation therapy was performed in 64 breast cancer patients. The postoperative short-term efficacy, safety, and cosmetic effects were assessed. Results Of the 64 patients, 1 case (1.6%) had local recurrence one year later, 7 cases (10.9%) had grade I postoperative radiation-induced lung injury, 10 cases (15.6%) had local hardening at the surgical sites, 8 cases (12.5 %) had changes in skin color, and 8 cases (12.5%) had pain at the surgical sites. Excellent or good levels of cosmetic effects were achieved in 95.3% of the patients. Conclusions The application of intraoperative radiation therapy with breast-conserving surgery can yield satisfactory short-term curative efficacy, a high level of clinical safety, and good cosmetic effects.

Sign in / Sign up

Export Citation Format

Share Document